These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 23151593

  • 1. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
    Jan R, Huang M, Lewis-Wambi J.
    Breast Cancer Res; 2012 Nov 14; 14(6):R146. PubMed ID: 23151593
    [Abstract] [Full Text] [Related]

  • 2. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
    Nelius T, Martinez-Marin D, Hirsch J, Miller B, Rinard K, Lopez J, de Riese W, Filleur S.
    Cell Death Dis; 2014 May 08; 5(5):e1210. PubMed ID: 24810046
    [Abstract] [Full Text] [Related]

  • 3. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
    Li J, Lu M, Jin J, Lu X, Xu T, Jin S.
    Cell Physiol Biochem; 2018 May 08; 50(1):136-149. PubMed ID: 30278449
    [Abstract] [Full Text] [Related]

  • 4. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
    Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.
    J Natl Cancer Inst; 2011 Apr 06; 103(7):538-52. PubMed ID: 21447808
    [Abstract] [Full Text] [Related]

  • 5. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.
    Anticancer Res; 2006 Apr 06; 26(3A):1773-84. PubMed ID: 16827106
    [Abstract] [Full Text] [Related]

  • 6. Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
    Watanabe T, Oba T, Tanimoto K, Shibata T, Kamijo S, Ito KI.
    PLoS One; 2021 Apr 06; 16(6):e0252822. PubMed ID: 34101751
    [Abstract] [Full Text] [Related]

  • 7. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J, Liu M, Yang L, Tu G, Zhu Q, Chen M, Cheng H, Luo H, Fu W, Li Z, Yang G.
    Breast Cancer Res; 2015 May 21; 17(1):69. PubMed ID: 25990368
    [Abstract] [Full Text] [Related]

  • 8. VAV3 mediates resistance to breast cancer endocrine therapy.
    Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA.
    Breast Cancer Res; 2014 May 28; 16(3):R53. PubMed ID: 24886537
    [Abstract] [Full Text] [Related]

  • 9. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death.
    Choi HJ, Lui A, Ogony J, Jan R, Sims PJ, Lewis-Wambi J.
    Breast Cancer Res; 2015 Jan 15; 17(1):6. PubMed ID: 25588716
    [Abstract] [Full Text] [Related]

  • 10. Pigment Epithelium-Derived Factor Alleviates Tamoxifen-Induced Endometrial Hyperplasia.
    Goldberg K, Bar-Joseph H, Grossman H, Hasky N, Uri-Belapolsky S, Stemmer SM, Chuderland D, Shalgi R, Ben-Aharon I.
    Mol Cancer Ther; 2015 Dec 15; 14(12):2840-9. PubMed ID: 26450919
    [Abstract] [Full Text] [Related]

  • 11. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
    Godinho M, Meijer D, Setyono-Han B, Dorssers LC, van Agthoven T.
    J Cell Physiol; 2011 Jul 15; 226(7):1741-9. PubMed ID: 21506106
    [Abstract] [Full Text] [Related]

  • 12. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
    Giannoudis A, Malki MI, Rudraraju B, Mohhamed H, Menon S, Liloglou T, Ali S, Carroll JS, Palmieri C.
    Breast Cancer Res; 2020 Nov 16; 22(1):126. PubMed ID: 33198803
    [Abstract] [Full Text] [Related]

  • 13. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.
    Wu M, Soler DR, Abba MC, Nunez MI, Baer R, Hatzis C, Llombart-Cussac A, Llombart-Bosch A, Aldaz CM.
    Mol Cancer Res; 2007 Dec 16; 5(12):1285-95. PubMed ID: 18171986
    [Abstract] [Full Text] [Related]

  • 14. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
    Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, Ellis IO, Gee JM.
    Breast Cancer Res Treat; 2010 Jan 16; 119(2):283-93. PubMed ID: 19238537
    [Abstract] [Full Text] [Related]

  • 15. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
    Perez White B, Molloy ME, Zhao H, Zhang Y, Tonetti DA.
    Mol Cancer; 2013 May 01; 12():34. PubMed ID: 23634843
    [Abstract] [Full Text] [Related]

  • 16. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer.
    Jia Y, Zhou J, Luo X, Chen M, Chen Y, Wang J, Xiong H, Ying X, Hu W, Zhao W, Deng W, Wang L.
    Cell Signal; 2018 Jan 01; 42():165-175. PubMed ID: 28988130
    [Abstract] [Full Text] [Related]

  • 17. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
    Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL, Majumder S.
    Cancer Res; 2012 Oct 01; 72(19):5048-59. PubMed ID: 22875023
    [Abstract] [Full Text] [Related]

  • 18. IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21.
    Lui AJ, Geanes ES, Ogony J, Behbod F, Marquess J, Valdez K, Jewell W, Tawfik O, Lewis-Wambi J.
    Cancer Lett; 2017 Jul 28; 399():29-43. PubMed ID: 28411130
    [Abstract] [Full Text] [Related]

  • 19. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
    Gao P, Wang X, Jin Y, Hu W, Duan Y, Shi A, Du Y, Song D, Yang M, Li S, Han B, Zhao G, Zhang H, Fan Z, Miao QR.
    Breast Cancer Res; 2018 Sep 12; 20(1):112. PubMed ID: 30208932
    [Abstract] [Full Text] [Related]

  • 20. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
    Barua D, Sultana A, Islam MN, Cox F, Gupta A, Gupta S.
    BMC Cancer; 2023 Mar 30; 23(1):288. PubMed ID: 36997866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.